Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis

Respiratory Medicine

Volumn 108, Issue 7, 2014, Pages 1031-1039

  Ohshimo, Shinichiro ^a   Ishikawa, Nobuhisa ^a   Horimasu, Yasushi ^a   Hattori, Noboru ^a   Hirohashi, Nobuyuki ^a   Tanigawa, Koichi ^a   Kohno, Nobuoki ^a   Bonella, Francesco ^b   Guzman, Josune ^c   Costabel, Ulrich ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Biomarker; Interstitial lung disease; Outcome; Survival

Indexed keywords

CC CHEMOKINE LIGAND 18; CHEMOKINE; GLYCOPROTEIN; KL 6 PROTEIN; UNCLASSIFIED DRUG; BETA CHEMOKINE; BIOLOGICAL MARKER; CCL18 PROTEIN, HUMAN; MUC1 PROTEIN, HUMAN; MUCIN 1;

ACCURACY; AGED; ARTICLE; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; VITAL CAPACITY; ACUTE DISEASE; BLOOD; EVALUATION STUDY; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; TOTAL LUNG CAPACITY;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; CHEMOKINES, CC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; MUCIN-1; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TOTAL LUNG CAPACITY;

EID: 84902370988     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.04.009     Document Type: Article

References (30)

1. F.J. Martinez, S. Safrin, D. Weycker, K.M. Starko, W.Z. Bradford, T.E. King Jr., K.R. Flaherty, D.A. Schwartz, P.W. Noble, G. Raghu, and K.K. Brown The clinical course of patients with idiopathic pulmonary fibrosis Ann Intern Med 142 2005 963 967
2. American Thoracic Society (ATS) and the European Respiratory Society (ERS) International multidisciplinary consensus classification of the idiopathic interstitial pneumonias Am J Respir Crit Care Med 165 2002 277 304
3. H.R. Collard, B.B. Moore, K.R. Flaherty, K.K. Brown, R.J. Kaner, T.E. King Jr., J.A. Lasky, J.E. Loyd, I. Noth, M.A. Olman, G. Raghu, J. Roman, J.H. Ryu, D.A. Zisman, G.W. Hunninghake, T.V. Colby, J.J. Egan, D.M. Hansell, T. Johkoh, N. Kaminski, D.S. Kim, Y. Kondoh, D.A. Lynch, J. Muller-Quernheim, J.L. Myers, A.G. Nicholson, M. Selman, G.B. Toews, A.U. Wells, and F.J. Martinez Acute exacerbations of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 176 2007 636 643
4. D.S. Kim, J.H. Park, B.K. Park, J.S. Lee, A.G. Nicholson, and T. Colby Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features Eur Respir J 27 2006 143 150
5. N. Kohno, S. Kyoizumi, Y. Awaya, H. Fukuhara, M. Yamakido, and M. Akiyama New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6 Chest 96 1989 68 73
6. S. Ohshimo, F. Bonella, U. Sommerwerck, H. Teschler, M. Kamler, H.G. Jakob, N. Kohno, J. Guzman, and U. Costabel Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation J Heart Lung Transplant 30 2011 1374 1380
7. A. Yokoyama, N. Kohno, H. Hamada, M. Sakatani, E. Ueda, K. Kondo, Y. Hirasawa, and K. Hiwada Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis Am J Respir Crit Care Med 158 1998 1680 1684
8. A. Prasse, D.V. Pechkovsky, G.B. Toews, M. Schafer, S. Eggeling, C. Ludwig, M. Germann, F. Kollert, G. Zissel, and J. Muller-Quernheim CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis Arthritis Rheum 56 2007 1685 1693
9. A. Prasse, C. Probst, E. Bargagli, G. Zissel, G.B. Toews, K.R. Flaherty, M. Olschewski, P. Rottoli, and J. Muller-Quernheim Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 179 2009 717 723
10. Ohshimo S KL-6 and CCL18 as predictors for acute exacerbation in idiopathic pulmonary fibrosis [abstract] Am J Respir Crit Care Med 2012 185
11. G. Raghu, H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, T.V. Colby, J.F. Cordier, K.R. Flaherty, J.A. Lasky, D.A. Lynch, J.H. Ryu, J.J. Swigris, A.U. Wells, J. Ancochea, D. Bouros, C. Carvalho, U. Costabel, M. Ebina, D.M. Hansell, T. Johkoh, D.S. Kim, T.E. King Jr., Y. Kondoh, J. Myers, N.L. Muller, A.G. Nicholson, L. Richeldi, M. Selman, R.F. Dudden, B.S. Griss, S.L. Protzko, and H.J. Schunemann An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 2011 788 824
12. M.R. Miller, R. Crapo, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, P. Enright, C.P. van der Grinten, P. Gustafsson, R. Jensen, D.C. Johnson, N. MacIntyre, R. McKay, D. Navajas, O.F. Pedersen, R. Pellegrino, G. Viegi, and J. Wanger General considerations for lung function testing Eur Respir J 26 2005 153 161
13. H.R. Collard, E. Yow, L. Richeldi, K.J. Anstrom, C. Glazer IPFnet investigators Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials Respir Res 14 2013 73
14. K. Fujimoto, H. Taniguchi, T. Johkoh, Y. Kondoh, K. Ichikado, H. Sumikawa, T. Ogura, K. Kataoka, T. Endo, A. Kawaguchi, and N.L. Muller Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality Eur Radiol 22 2012 83 92
15. R.M. du Bois, D. Weycker, C. Albera, W.Z. Bradford, U. Costabel, A. Kartashov, T.E. King Jr., L. Lancaster, P.W. Noble, S.A. Sahn, M. Thomeer, D. Valeyre, and A.U. Wells Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference Am J Respir Crit Care Med 184 2011 1382 1389
16. A.L. Peljto, Y. Zhang, T.E. Fingerlin, S.F. Ma, J.G. Garcia, T.J. Richards, L.J. Silveira, K.O. Lindell, M.P. Steele, J.E. Loyd, K.F. Gibson, M.A. Seibold, K.K. Brown, J.L. Talbert, C. Markin, K. Kossen, S.D. Seiwert, E. Murphy, I. Noth, M.I. Schwarz, N. Kaminski, and D.A. Schwartz Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis JAMA 309 2013 2232 2239
17. W.E. Lawson, and J.E. Loyd The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease? Proc Am Thorac Soc 3 2006 345 349
18. M. Zorzetto, I. Ferrarotti, R. Trisolini, L. Lazzari Agil, R. Scabini, M. Novo, A. De Silvestri, M. Patelli, M. Martinetti, M. Cuccia, V. Poletti, E. Pozzi, and M. Luisetti Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 168 2003 330 334
19. K.D. Tsakiri, J.T. Cronkhite, P.J. Kuan, C. Xing, G. Raghu, J.C. Weissler, R.L. Rosenblatt, J.W. Shay, and C.K. Garcia Adult-onset pulmonary fibrosis caused by mutations in telomerase Proc Natl Acad Sci U S A 104 2007 7552 7557
20. H.R. Collard, C.S. Calfee, P.J. Wolters, J.W. Song, S.B. Hong, S. Brady, A. Ishizaka, K.D. Jones, T.E. King Jr., M.A. Matthay, and D.S. Kim Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol 299 2010 L3 L7
21. S. Tajima, K. Oshikawa, S. Tominaga, and Y. Sugiyama The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis Chest 124 2003 1206 1214
22. K. Konishi, K.F. Gibson, K.O. Lindell, T.J. Richards, Y. Zhang, R. Dhir, M. Bisceglia, S. Gilbert, S.A. Yousem, J.W. Song, D.S. Kim, and N. Kaminski Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 180 2009 167 175
23. T.J. Richards, N. Kaminski, F. Baribaud, S. Flavin, C. Brodmerkel, D. Horowitz, K. Li, J. Choi, L.J. Vuga, K.O. Lindell, M. Klesen, Y. Zhang, and K.F. Gibson Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 185 2012 67 76
24. N.M. Korthagen, C.H. van Moorsel, N.P. Barlo, H.J. Ruven, A. Kruit, M. Heron, J.M. van den Bosch, and J.C. Grutters Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis Respir Med 105 2011 106 113
25. K. Tachibana, Y. Inoue, A. Nishiyama, C. Sugimoto, A. Matsumuro, M. Hirose, M. Kitaichi, M. Akira, T. Arai, and S. Hayashi Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: serum IL-7 as a prognostic marker Sarcoidosis Vasc Diffuse Lung Dis 28 2011 113 122
26. A. Yokoyama, K. Kondo, M. Nakajima, T. Matsushima, T. Takahashi, M. Nishimura, M. Bando, Y. Sugiyama, Y. Totani, T. Ishizaki, H. Ichiyasu, M. Suga, H. Hamada, and N. Kohno Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis Respirology 11 2006 164 168
27. Y. Inoue, E. Barker, E. Daniloff, N. Kohno, K. Hiwada, and L.S. Newman Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis Am J Respir Crit Care Med 156 1997 109 115
28. A. Seko, T. Ohkura, H. Ideo, and K. Yamashita Novel O-linked glycans containing 6'-sulfo-Gal/GalNAc of MUC1 secreted from human breast cancer YMB-S cells: possible carbohydrate epitopes of KL-6(MUC1) monoclonal antibody Glycobiology 22 2012 181 195
29. S. Ohshimo, A. Yokoyama, N. Hattori, N. Ishikawa, Y. Hirasawa, and N. Kohno KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts Biochem Biophys Res Commun 338 2005 1845 1852
30. Y. Horimasu, N. Hattori, N. Ishikawa, S. Kawase, S. Tanaka, K. Yoshioka, A. Yokoyama, N. Kohno, F. Bonella, J. Guzman, S. Ohshimo, and U. Costabel Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels Respir Med 106 2012 1756 1764